Apitegromab SAPPHIRE Phase 3 succeeds — first muscle-directed therapy to win in SMA
The headline
Scholar Rock's apitegromab (SRK-015, selective latent myostatin inhibitor) hit its Phase 3 primary endpoint in the SAPPHIRE trial for nonambulatory Type II/III SMA patients on background SMN therapy (nusinersen or risdiplam). Data was presented at the Cure SMA Annual Research & Clinical Care Meeting (June 2025, Anaheim) and published in Lancet Neurology 2025.
Key numbers:
- +1.8-point gain in HFMSE (Hammersmith Functional Motor Scale Expanded) vs placebo (p = 0.0192)
- 30.4% of treated patients achieved ≥3-point HFMSE improvement vs 12.5% placebo
- Well-tolerated on top of SMN-restoring therapy
Why it matters
This is the first muscle-directed therapy to succeed in a pivotal SMA trial. It validates the combination-therapy framework the 2026 SMA Congress (Budapest) then elaborated upon: SMN restoration + muscle/NMJ adjunct is the rational next step.
Apitegromab inhibits the activation of latent myostatin selectively (not mature myostatin), which reduces off-target effects on smooth muscle and other tissues.
Mechanism class
Apitegromab sits in a growing class of muscle-directed biologics:
- Apitegromab — anti-latent myostatin (Scholar Rock) — now Phase 3 positive
- Taldefgrobep alfa (GYM329 / RO7204239) — anti-latent myostatin (Roche), MANATEE trial with risdiplam combo in ambulatory SMA Type II/III (Phase 2/3)
- ARGX-119 — MuSK agonist Fab (argenx), NMJ rescue (Phase 1 complete, SMA Congress 2026 O28)
In-platform
Apitegromab was already seeded into /drugs. Status: Phase 3 positive readout.
What we are doing
Running a comparative mechanism card across the three muscle-directed programmes (apitegromab vs. GYM329 vs. ARGX-119) and adding it to /directions as a "muscle adjunct landscape" page.